Characterization of a new potent heparin. 7th communication: A comparative study of a new potent heparin in human after i.v. application.
The anticoagulant effect of a new potent heparin was compared with commercial heparin after a single i.v. application in human subjects. Determinations of thrombin time, whole-blood clotting time, activated partial thromboplastin time and plasma heparin levels using factor Xa inactivation assay were performed 5, 10, 15, 30 and 60 min after application. The new potent heparin was 1.5 to 2.0 times more effective than commercial heparin per mg dry weight depending upon the coagulation tests used and the length of observation period. In addition, determinations of biochemical and haematological parameters, 24 h after heparin application indicated no signs of any adverse effect.
D000328:Adult; D000925:Anticoagulants; D001777:Blood Coagulation / Q000187:drug effects; D005260:Female; D006493:Heparin / Q000008:administration & dosage / Q000494:pharmacology*; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D010314:Partial Thromboplastin Time; D013918:Thrombin Time; D013997:Time Factors
D000925:Anticoagulants; D006493:Heparin